Literature DB >> 16437637

Impairment of IFN-alpha production capacity in patients with hepatitis C virus and the risk of the development of hepatocellular carcinoma.

Kazuko Uno1, Yoshiki Suginoshita, Kazuhiro Kakimi, Fuminori Moriyasu, Mayumi Hirosaki, Taro Shirakawa, Tsunataro Kishida.   

Abstract

AIM: To determine the utility of interferon (IFN)-alpha production capacity in patients with hepatitis C virus (HCV) infection for the measurement of immuno-surveillance potential and for the early detection of hepatocellular carcinoma (HCC) by investigating the Sendai virus (HVJ) stimulated IFN-alpha production capacity of patients with HCV infection.
METHODS: HVJ stimulated IFN-alpha production was determined in a large number of patients with HCV infection and the development of HCC was monitored for 3 years in patients with liver cirrhosis (LC).
RESULTS: IFN-alpha production capacity decreases gradually with the progression of liver disease from chronic hepatitis (CH) to HCC. A significant correlation between the duration of HCV infection and impaired IFN-alpha production capacity was observed. IFN-alpha production in patients who developed HCC within 3 years was significantly lower than that of patients who remained in LC without developing HCC.
CONCLUSION: Measurement of IFN-alpha production in LC patients may be useful for the early detection of HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437637      PMCID: PMC4725153          DOI: 10.3748/wjg.v11.i46.7330

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Relationship between natural killer activity and development of hepatocellular carcinoma in patients with cirrhosis of the liver.

Authors:  T Nakajima; N Mizushima; K Kanai
Journal:  Jpn J Clin Oncol       Date:  1987-12       Impact factor: 3.019

2.  Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection.

Authors:  Masahisa Jinushi; Tetsuo Takehara; Tomohide Tatsumi; Tatsuya Kanto; Takuya Miyagi; Takahiro Suzuki; Yoshiyuki Kanazawa; Naoki Hiramatsu; Norio Hayashi
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

Review 3.  Interferon-alpha in tumor immunity and immunotherapy.

Authors:  Filippo Belardelli; Maria Ferrantini; Enrico Proietti; John M Kirkwood
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

4.  Action of recombinant alpha interferon against experimental and spontaneous metastases in a murine model.

Authors:  P Ramani; F R Balkwill
Journal:  Int J Cancer       Date:  1989-01-15       Impact factor: 7.396

5.  Correlation between the severity of clinicopathological parameters and whole blood interferon-alpha production capacity in active phase IgA nephropathy patients.

Authors:  Kiichi Shirakawa; Eri Muso; Fumiaki Nogaki; Mari Maeda; Takahide Kawamura; Takahiko Ono; Miwa Yoshimoto; Kazuko Uno; Tsunatarou Kishida; Shigetake Sasayama
Journal:  Nephron       Date:  2002-01       Impact factor: 2.847

6.  Effect of recombinant human interferon-alpha A/D on in vivo murine tumor cell growth.

Authors:  K Uno; S Shimizu; K Inaba; M Kitaura; K Nakahira; T Kato; Y Yamaguchi; S Muramatsu
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

7.  Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines.

Authors:  Hélène Gary-Gouy; Pierre Lebon; Ali H Dalloul
Journal:  J Interferon Cytokine Res       Date:  2002-06       Impact factor: 2.607

8.  Risk assessment in chronic myelomonocytic leukemia (CMML).

Authors:  U Germing; A Kündgen; N Gattermann
Journal:  Leuk Lymphoma       Date:  2004-07

9.  Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice.

Authors:  L M Reid; N Minato; I Gresser; J Holland; A Kadish; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

Review 10.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

View more
  2 in total

1.  Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C.

Authors:  Koji Onomoto; Shiho Morimoto; Takahisa Kawaguchi; Hidenori Toyoda; Masami Tanaka; Masahiko Kuroda; Kazuko Uno; Takashi Kumada; Fumihiko Matsuda; Kunitada Shimotohno; Takashi Fujita; Yoshiki Murakami
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

2.  IFN production ability and healthy ageing: mixed model analysis of a 24 year longitudinal study in Japan.

Authors:  Kazuko Uno; Katsumi Yagi; Masayo Yoshimori; Mari Tanigawa; Toshikazu Yoshikawa; Setsuya Fujita
Journal:  BMJ Open       Date:  2013-01-11       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.